Drug Profile
JX 929
Alternative Names: JX-929; vvDD-CDSRLatest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Jennerex
- Developer University of Pittsburgh
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Cytosine deaminase modulators; Epidermal growth factor receptor modulators; Somatostatin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural, Injection)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Apr 2016 Phase I development is ongoing in USA (IV & Intratumoural)